Benitec Biopharma Inc.
NASDAQ•BNTC
CEO: Dr. Jerel A. Banks M.D., Ph.D.
Sector: Healthcare
Industry: Biotechnology
Listing Date: 2014-06-24
Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. Benitec Biopharma Inc. was incorporated in 1995 and is headquartered in Hayward, California.
Contact Information
Market Cap
$306.57M
P/E (TTM)
-10.4
38.2
Dividend Yield
--
52W High
$17.15
52W Low
$9.70
52W Range
Rank48Top 64.4%
3.3
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Weak • 3.3 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025
Financial Dashboard
Q1 2026 Data
Revenue
$0.00+0.00%
4-Quarter Trend
EPS
-$0.22-54.17%
4-Quarter Trend
FCF
-$3.35M-26.93%
4-Quarter Trend
2026 Q1 Earnings Highlights
Key Highlights
Strong Cash Position Maintained Cash reserves total $94.6M end of period, significantly higher than $67.9M held at September 30, 2024.
BB-301 Clinical Success Noted BB-301 Cohort 1 achieved 100% statistical response rate; FDA granted Fast Track designation for OPMD treatment.
Reduced Operating Cash Burn Cash used in operations reduced to $3.35M this quarter, compared to $4.59M used in the prior comparable period.
Lead Asset Development Progress BB-301 is the lead agent for OPMD; strategy focuses on advancing clinical trials through key inflection points.
Risk Factors
Net Loss Significantly Widened Net loss increased to $9.0M for the quarter, compared to $5.1M loss reported in the prior year period.
G&A Expense Driven by Stock General administrative expenses rose sharply to $6.43M, primarily due to $5.18M in share-based compensation expense.
Internal Control Material Weakness Material weakness identified in internal controls over share-based compensation calculation review process; remediation is underway.
Dependence on Future Financing Expect continued operating losses; ability to continue as going concern depends on obtaining adequate financing resources.
Outlook
Post-Period Financing Closed Closed November 2025 offerings raising approximately $100M gross proceeds before deducting underwriting discounts and fees.
BB-301 Trial Follow-up Continues Continue BB-301 Phase 1b/2a trial follow-up; interim safety and efficacy results expected to be available every 180 days.
ATM Facility Remains Available Maintain access to $75M Sales Agreement for future capital needs; no sales utilized during the current reporting quarter.
Future Funding Requirements Uncertain Future capital needs depend heavily on clinical trial costs, regulatory timing, and successful intellectual property defense.
Peer Comparison
Revenue (TTM)
AMRN$225.62M
$75.27M
DMAC$13.80M
Gross Margin (Latest Quarter)
100.0%
99.9%
93.3%
Key Metrics
Symbol | Market Cap | P/E (TTM) | ROE (TTM) | Debt to Assets |
|---|---|---|---|---|
| RAPT | $580.47M | -9.0 | -61.8% | 1.6% |
| DSGN | $528.62M | -7.8 | -30.6% | 0.8% |
| DBVT | $497.09M | -3.3 | -295.2% | 0.0% |
Long-Term Trends
Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
N/M
Revenue Volatile
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
0%
Cash Flow Needs Attention
Research & Insights
Next earnings:Feb 13, 2026
EPS:-$0.23
|Revenue:-
Reports
All Years
Form 10-Q - Q1 2026
Period End: Sep 30, 2025|Filed: Nov 14, 2025|Revenue: $0.00+0.0%|EPS: $-0.22-54.2%N/AForm 10-K - FY 2025
Period End: Jun 30, 2025|Filed: Sep 22, 2025|Revenue: $0.00+0.0%|EPS: $-1.05+60.8%N/AForm 10-Q - Q3 2025
Period End: Mar 31, 2025|Filed: May 14, 2025|Revenue: $0.00-100.0%|EPS: $-0.24+4.3%N/AForm 10-Q - Q2 2025
Period End: Dec 31, 2024|Filed: Feb 14, 2025|Revenue: $0.00+0.0%|EPS: $-0.33-75.0%N/AForm 10-Q - Q1 2025
Period End: Sep 30, 2024|Filed: Nov 14, 2024|Revenue: $0.00+0.0%|EPS: $-0.48-65.2%N/AForm 10-K - FY 2024
Period End: Jun 30, 2024|Filed: Sep 26, 2024|Revenue: $216.00K+188.0%|EPS: $-2.68+81.0%N/AForm 10-Q - Q3 2024
Period End: Mar 31, 2024|Filed: May 13, 2024|Revenue: $6.00K-88.9%|EPS: $-0.23-91.4%N/AForm 10-Q - Q2 2024
Period End: Dec 31, 2023|Filed: Feb 13, 2024|Revenue: $0.00-100.0%|EPS: $-1.32-18.0%N/A